![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1566962
Àΰø ÃéÀå ±â±â ½Ã½ºÅÛ ½ÃÀå : ±â±â À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ±âȸ ºÐ¼® ¹× »ê¾÷ ¿¹Ãø(2024-2033³â)Artificial Pancreas Devices Systems Market By Device Type (Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems), By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033 |
Àΰø ÃéÀå ±â±â ½Ã½ºÅÛ ½ÃÀåÀº 2023³â 4¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2024-2033³â±îÁö ¿¬Æò±Õ 8.8% ¼ºÀåÇÏ¿© 2033³â¿¡´Â 8¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Àΰø ÃéÀå ±â±â´Â °Ç°ÇÑ ÃéÀåÀÇ Æ÷µµ´ç Á¶Àý ±â´ÉÀ» ¸ð¹æÇÏ¿© ÃÖÀûÀÇ Ç÷´ç ¼öÁØÀ» À¯ÁöÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. ÀÌ ÀÇ·á ±â¼úÀº ÁÖ·Î ´ç´¢º´, ƯÈ÷ Á¦1Çü ´ç´¢º´ ȯÀÚÀÇ Ç÷´ç ¼öÄ¡¸¦ ¸ð´ÏÅ͸µÇϰí Á¶ÀýÇϱâ À§ÇØ °í¾ÈµÈ ÀÇ·á ±â¼úÀÔ´Ï´Ù. ÀÌ ±â±â´Â ÀÒ¾î¹ö¸° ±â´ÉÀ» ȸº¹Çϰí Àΰ£ÀÇ ´É·ÂÀ» Çâ»ó½Ã۰í Àü¹ÝÀûÀÎ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â °ÍÀ» ¸ñÇ¥·ÎÇÕ´Ï´Ù.
Àΰø ÃéÀå ±â±â ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ´ç´¢º´, ƯÈ÷ Á¦ 1 Çü ´ç´¢º´ÀÇ Àü ¼¼°è À¯º´·üÀÇ ³î¶ó¿î Áõ°¡, Àΰø ÃéÀå ±â±â ½Ã½ºÅÛÀÇ ÀÌÁ¡¿¡ ´ëÇÑ È¯ÀÚ ¹× ÀÇ·á ¼ºñ½º Á¦°øÀÚÀÇ ÀÎ½Ä Áõ°¡°¡ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. 700¸¸ ¸íÀÇ ¼ºÀÎÀÌ ´ç´¢º´À» ¾Î°í ÀÖ½À´Ï´Ù. ÀÌ ¼ýÀÚ´Â 2030³â¿¡´Â 6¾ï 4,300¸¸ ¸í, 2045³â¿¡´Â 7¾ï 8,300¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, 2021³â¿¡´Â ´ç´¢º´À¸·Î ÀÎÇØ ¾à 670¸¸ ¸íÀÌ »ç¸ÁÇÑ °ÍÀ¸·Î º¸°íµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ƯÈ÷ ½ÅÈï±¹ÀÇ ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´õ ¸¹Àº ȯÀÚµéÀÌ Ã·´Ü ´ç´¢º´ °ü¸® ±â¼úÀ» ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. °°Àº ¼Ò½ÄÅë¿¡ µû¸£¸é ´ç´¢º´Àº 2021³â¿¡ ÃÖ¼Ò 9,660¾ï ´Þ·¯ÀÇ ÀÇ·áºñ ÁöÃâÀ» ÃÊ·¡Çß´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ Àΰø ÃéÀå ±â±â ½Ã½ºÅÛ°ú µðÁöÅÐ °Ç° Ç÷§Æû ¹× ½º¸¶Æ®Æù ¾ÖÇø®ÄÉÀ̼ÇÀÇ ÅëÇÕÀº ȯÀÚ Âü¿©¸¦ °ÈÇÏ°í ´õ ³ªÀº ¿ø°Ý ¸ð´ÏÅ͸µ ¹× °ü¸®¸¦ °¡´ÉÇϰÔÇÏ¿© ½ÃÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀ¸·Î ÀÛ¿ëÇÒ °ÍÀÔ´Ï´Ù. ±×·¯³ª Àΰø ÃéÀå ±â±â ½Ã½ºÅÛ°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀº ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦ÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ´ëºÎºÐÀÇ ±¹°¡¿¡¼ Àα¸ÀÇ ¿ä±¸¸¦ ÃæÁ·½Ãų ¼ö ÀÖ´Â ÀûÀýÇÑ ÀÇ·á ½Ã¼³ÀÌ ºÎÁ·Çϰí Á¢±Ù¼ºÀÌ Á¦ÇÑÀûÀ̶ó´Â Á¡µµ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÀúÇØ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¹Ý´ë·Î ¼¾¼ ±â¼ú, Àν¶¸° Àü´Þ ½Ã½ºÅÛ ¹× Á¦¾î ¾Ë°í¸®ÁòÀÇ Áö¼ÓÀûÀÎ °³¼±Àº Àΰø ÃéÀå ±â±â ½Ã½ºÅÛÀÇ ¼º´É°ú ½Å·Ú¼ºÀ» Çâ»ó½ÃÄÑ ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ÃÀå È®´ë¿¡ À¯ÀÍÇÑ ±âȸ¸¦ Á¦°ø ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ´ç´¢º´ Ä¡·á ¹× °ü¸®¸¦ °³¼±Çϱâ À§ÇÑ ÀÌ´Ï¼ÅÆ¼ºê°¡ Áõ°¡ÇÔ¿¡ µû¶ó Àΰø ÃéÀå ±â±â ½Ã½ºÅÛ Ã¤Åÿ¡ ´ëÇÑ Àμ¾Æ¼ºê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¼¼°èº¸°Ç±â±¸(WHO)´Â 2021³â 4¿ù WHO ¼¼°è´ç´¢º´Çù¾à(WHO World Diabetes Compact)À̶ó´Â ÀÌ´Ï¼ÅÆ¼ºê¸¦ Ãâ¹ü½ÃÄ×½À´Ï´Ù. ÀÌ ÀÌ´Ï¼ÅÆ¼ºê´Â ´ç´¢º´ÀÇ À§ÇèÀ» ÁÙÀÌ°í ´ç´¢º´ ȯÀÚ°¡ Àú·ÅÇÑ °¡°ÝÀ¸·Î ¾çÁúÀÇ Ä¡·á¿Í °ü¸®¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.
Àΰø ÃéÀå ±â±â ½Ã½ºÅÛ »ê¾÷Àº ±â±â À¯Çü, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù. ±â±â À¯Çüº°·Î ½ÃÀåÀº ÀÓ°è°ª ¼½ºÆæµå ±â±â ½Ã½ºÅÛ, CTR(control-to-range) ½Ã½ºÅÛ, CTT(control-to-target) ½Ã½ºÅÛÀ¸·Î ³ª´¹´Ï´Ù. ÃÖÁ¾»ç¿ëÀÚ¿¡ µû¶ó º´¿ø, Ŭ¸®´Ð, ÀçÅÃÀÇ·á·Î ³ª´¹´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«·Î ºÐ¼®µË´Ï´Ù.
ÁÖ¿ä Á¶»ç °á°ú
±â±â À¯Çüº°·Î´Â ÀÓ°è°ª ¼½ºÆæµðµå ±â±â ½Ã½ºÅÛ ºÎ¹®ÀÌ 2023³â ½ÃÀå Á¡À¯À² 1À§¸¦ Â÷ÁöÇß½À´Ï´Ù.
ÃÖÁ¾»ç¿ëÀÚº°·Î´Â 2023³â ȨÄÉ¾î ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ½ÃÀå¿¡¼ Áö¹èÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
º» º¸°í¼ÀÇ Ä¿½ºÅ͸¶ÀÌ¡ °¡´É¼º(Ãß°¡ ºñ¿ë ¹× ÀÏÁ¤ÀÌ ÇÊ¿äÇÕ´Ï´Ù.)
The artificial pancreas devices systems market was valued at $0.4 billion in 2023, and is projected to reach $0.8 billion by 2033, growing at a CAGR of 8.8% from 2024 to 2033.
Artificial pancreas device is a medical device that mimics the glucose-regulating function of a healthy pancreas, aiming to maintain optimal blood sugar levels. This medical technology is primarily designed to monitor and regulate blood glucose levels in individuals suffering from diabetes, particularly those with type 1 diabetes. These devices aim to restore lost functions, enhance human capabilities, and improve overall quality of life.
The growth of the artificial pancreas devices systems market is majorly driven by alarming increase in global prevalence of diabetes, particularly type 1 diabetes and rise in awareness among patients and healthcare providers about the benefits of artificial pancreas systems. According to the 2021 key findings of IDF Diabetes Atlas 10th edition, approximately 537 million adults are suffering diabetes. This number is estimated to reach 643 million by 2030 and 783 million by 2045. Around 6.7 million deaths were reported due to diabetes in 2021. Moreover, increase in healthcare expenditure, particularly in emerging economies, allows more patients to access advanced diabetes management technologies. As per the same source, diabetes was responsible for at least $966 billion dollars in health expenditure in 2021. Furthermore, the integration of artificial pancreas devices systems with digital health platforms and smartphone applications enhances patient engagement and allows for better remote monitoring and management, which acts as the key driving force of the market. However, high cost associated with the artificial pancreas devices systems restrains the growth of the market. Moreover, lack of appropriate health facilities to meet population needs in most countries and limited access act as the key deterrent factors of the market. On the contrary, continuous improvements in sensor technology, insulin delivery systems, and control algorithms enhance the performance and reliability of artificial pancreas systems, which are expected to offer remunerative opportunities for the expansion of the global market during the forecast period. In addition, increase in initiatives aimed at improving diabetes care and management are providing incentives for the adoption of artificial pancreas systems. For instance, the World Health Organization launched an initiative in April 2021, WHO Global Diabetes Compact. The initiative aims to reduce the risk of diabetes and ensure that diabetic individuals have access to affordable and quality treatment and care.
The artificial pancreas devices systems industry is segmented into device type, end user, and region. By device type, the market is divided into threshold suspend device systems, control-to-range (CTR) systems, and control-to-target (CTT) systems. On the basis of end user, it is divided into hospitals, clinics, homecare. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By device type, the threshold suspend device systems segment dominated the market, in terms of share, in 2023.
Depending on end user, the homecare segment captured the largest share in 2023.
Region wise, North America holds a dominant position in the market in 2023.
Competition Analysis
Competitive analysis and profiles of the major players in the global artificial pancreas devices systems market include Medtronic plc, Bigfoot Biomedical, Inc., Johnson & Johnson, Tandem Diabetes Care, Inc., Pancreum, Inc, TypeZero Technologies, LLC, Beta Bionics, Inc, Insulate Corporation, Diabeloop, and Inreda Diabetic. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.
Additional benefits you will get with this purchase are:
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)